Arbutus Biopharma (ABUS) Profit After Tax (2013 - 2026)
Arbutus Biopharma (ABUS) posted Profit After Tax of $169.7 million for Q1 2026, up 4617.97% sequentially from -$3.8 million in Q4 2025, and up 791.02% YoY from $19.0 million in Q1 2025.
Arbutus Biopharma (ABUS) Profit After Tax (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Profit After Tax for 14 years, with the latest figure at $169.7 million in Q1 2026.
- Quarterly Profit After Tax rose 791.02% year-over-year to $169.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.7 million (up 309.81% YoY) and the FY2025 annual result came in at -$33.5 million, up 52.09% from the prior year.
- Profit After Tax grew to $169.7 million in Q1 2026 per ABUS's latest filing, from -$3.8 million in the prior quarter.
- Over five years, Profit After Tax peaked at $169.7 million in Q1 2026 and troughed at -$24.6 million in Q1 2025.
- A 5-year average of -$4.5 million and a median of -$17.1 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax sank 37.38% in 2025, then surged 791.02% in 2026.
- Over 5 years, Profit After Tax stood at -$21.4 million in 2022, then climbed by 9.82% to -$19.3 million in 2023, then soared by 35.11% to -$12.5 million in 2024, then jumped by 70.03% to -$3.8 million in 2025, then jumped by 4617.97% to $169.7 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $169.7 million, -$3.8 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -5.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.19 Mn |
| Mar 31, 2026 | 169.70 Mn |
| Dec 31, 2025 | -3.76 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | 2.52 Mn |
| Mar 31, 2025 | -24.56 Mn |
| Dec 31, 2024 | -12.53 Mn |
| Sep 30, 2024 | -19.72 Mn |
| Jun 30, 2024 | -19.80 Mn |
| Mar 31, 2024 | -17.88 Mn |
| Dec 31, 2023 | -19.31 Mn |
| Sep 30, 2023 | -20.10 Mn |
| Jun 30, 2023 | -17.09 Mn |
| Mar 31, 2023 | -16.34 Mn |
| Dec 31, 2022 | -21.42 Mn |
| Sep 30, 2022 | -18.47 Mn |
| Jun 30, 2022 | -14.19 Mn |
| Mar 31, 2022 | -15.77 Mn |
| Dec 31, 2021 | -21.47 Mn |
| Sep 30, 2021 | -19.19 Mn |